<SEC-DOCUMENT>0001937653-25-000012.txt : 20250305
<SEC-HEADER>0001937653-25-000012.hdr.sgml : 20250305
<ACCEPTANCE-DATETIME>20250305160820
ACCESSION NUMBER:		0001937653-25-000012
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250305
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250305
DATE AS OF CHANGE:		20250305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zymeworks Inc.
		CENTRAL INDEX KEY:			0001937653
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				883099146
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41535
		FILM NUMBER:		25710987

	BUSINESS ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709
		BUSINESS PHONE:		302-274-8744

	MAIL ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zymeworks Delaware Inc.
		DATE OF NAME CHANGE:	20220712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zyme-20250305.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9d5d0ff3-fe4a-435e-bf15-0ec2343d4c51,g:1e625152-6b29-46f4-847a-3baffa6d17a3,d:595d3b4458604c7f956e4f19b5652485-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>zyme-20250305</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001937653</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="zyme-20250305.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-05</xbrli:startDate><xbrli:endDate>2025-03-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i595d3b4458604c7f956e4f19b5652485_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;padding-left:170.2pt;padding-right:170.2pt;text-align:center"><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934 </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March&#160;5, 2025</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Zymeworks Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:32.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.928%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-41535</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">88-3099146</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></td><td colspan="6" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">108 Patriot Drive, Suite A</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Middletown</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">19709</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">302</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">274-8744</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:2.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.618%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.00001 par value per share</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ZYME</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESULTS OF OPERATIONS AND FINANCIAL CONDITION</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-21">March&#160;5, 2025</ix:nonNumeric>, Zymeworks Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the  three months and year ended December&#160;31, 2024. A copy of the press release is attached as Exhibit&#160;99.1 to&#160;this&#160;Current Report on Form&#160;8-K (this &#8220;Form 8-K&#8221;). </span></div><div style="margin-top:12pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;7.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGULATION FD DISCLOSURES</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company&#8217;s website (www.zymeworks.com), its investor relations website (ir.zymeworks.com), its news site (ir.zymeworks.com/press-releases), its publications site (zymeworks.com/publications) and its events and presentations site (ir.zymeworks.com/events-and-presentations). The Company uses these channels, as well as social media, including its X account (@ZymeworksInc) and LinkedIn account (www.linkedin.com/company/zymeworks), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.</span></div><div style="margin-top:12pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENTS AND EXHIBITS</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:18.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="ex991q42024_earningsxrelea.htm">Press Release dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="ex991q42024_earningsxrelea.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="ex991q42024_earningsxrelea.htm">March 5, 2025</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cover Page Interactive Data File (embedded as Inline XBRL document)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished under Items 2.02 and 7.01 of this Current Report on Form&#160;8-K&#160;and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="margin-bottom:8pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.064%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ZYMEWORKS INC.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:42.287%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.770%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.290%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date: March&#160;5, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leone Patterson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leone Patterson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Business Officer and Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991q42024_earningsxrelea.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia74eca56e7e24e589e0da48e640cde01_1"></div><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><img alt="zw_logo.jpg" src="zw_logo.jpg" style="height:125px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Zymeworks Provides Corporate Update and<br>Reports Fourth Quarter and Full Year 2024 Financial Results </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-&#9082; (FR&#9082;) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelin</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Acceleration of the planned investigational new drug (IND) application to mid-2025 for ZW251, an ADC engineered to target glypican-3 (GPC3) </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">U.S. Food and Drug Administration (FDA) granted accelerated approval of Ziihera&#174; (zanidatamab-hrii) for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (HER2+) (IHC 3+) second-line biliary tract cancer (BTC)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.15pt">Reported $324.2 million in cash resources as of December&#160;31, 2024, which when combined with certain anticipated regulatory milestone payments, provides a projected cash runway into </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">2H-2027</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">Will host conference call with management today at 4&#58;30 p.m. Eastern Time (ET)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Vancouver, British Columbia (March&#160;5, 2025) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8211; Zymeworks Inc. (Nasdaq&#58; ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financial results for the</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> fourth quarter and year ended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> December&#160;31, 2024 and provided a summary of recent business highlights.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8220;We significantly advanced our wholly-owned product pipeline during 2024, most notably with the initiation of first-in-human studies for ZW191 and ZW171, both designed to address critical needs for patients in the treatment of solid tumors,&#8221; said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. &#8220;In addition, we anticipate the IND submission for ZW251, an antibody-drug conjugate targeting GPC3, to be accelerated to mid-2025 due to a reprioritization of resources within our product pipeline. These development milestones highlight our commitment and progress in developing next-generation multifunctional biotherapeutics that address unmet medical needs and improve patient outcomes.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Galbraith continued, &#8220;Turning to our most advanced partnered product, Ziihera</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:107%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> (zanidatamab-hrii) achieved a major milestone with its accelerated approval and launch for HER2-positive biliary tract cancer. With initial uptake in biliary tract cancer in the US, we look forward to reporting on the outcomes of pending regulatory actions in the European Union and China in 2025 with our partners </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Jazz Pharmaceuticals and BeiGene, as well as the top-line results from the HERIZON-GEA-01 study of Ziihera</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> expected in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">2H-2025.&#8221;</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Recent Developments</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Wholly-Owned Programs</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">ZW191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In November 2024, we announced that the first patient has been dosed in our first-in-human Phase 1 trial (NCT06555744) to evaluate the safety and tolerability of the investigational therapy ZW191 in the treatment of advanced FR&#9082;-expressing solid tumors including ovarian, endometrial, and non-small cell lung (NSCLC) cancers. The Phase 1 trial is a two-part, multi-center, global study that aims to enroll 145 adult patients with advanced FR&#9082;-expressing cancers. We are currently enrolling patients at investigator sites in North America, Europe, and the Asia-Pacific region. Recruitment in the dose escalation portion of the study remains ongoing to evaluate the safety and tolerability of ZW191 in patients with advanced ovarian, endometrial, and NSCLC cancers, with secondary endpoints assessing pharmacokinetics and confirmed objective response rate. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ZW171</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In November 2024, at the annual Society for Immunotherapy of Cancer (SITC) Conference we shared a poster presentation titled &#8220;Mechanistic QSP modeling and translational strategy for determining a First-In-Human dose for ZW171, a bispecific 2+1 T cell engager (TCE) molecule targeting mesothelin and CD3&#8221; (Abstract #&#58; 1062), which demonstrates how a Quantitative System Pharmacology (QSP) model was developed for ZW171 using in vitro data, pharmacokinetics (PK) data from cynomolgus monkey, and literature data (e.g., CD3 receptors per T cells, number of T cells in central and peripheral compartments, and clinical PK data of mesothelin-targeting TCE) to facilitate the selection of the ZW171 starting dose for our Phase 1 clinical study. Recruitment in the dose escalation portion of the clinical study remains ongoing in patients with advanced ovarian and NSCLC cancers.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2024, we hosted an R&#38;D day highlighting continued clinical progress on our solid tumor programs in oncology and expansion into autoimmune and inflammatory diseases (AIID). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based on our encouraging preclinical results and the unique potential opportunity to help hepatocellular carcinoma patients, we have decided to reprioritize resources for the advancement of ZW251, for which an IND submission is now planned for mid-2025. As a result, we have paused preparations for the commencement of Phase 1 studies of ZW220 at this time. However, we believe ZW220 remains a highly differentiated, IND-ready ADC with encouraging preclinical data and strong commercial rationale with partnership potential. We look forward to providing future updates on the development for ZW220. </font></div><div><font><br></font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;This year, we are advancing another exciting antibody-drug conjugate toward IND submission and Phase 1 clinical studies, leveraging our proprietary ZD06519 payload platform and an optimized antibody framework designed to precisely align with both disease biology and target dynamics,&#8221; stated Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. &#8220;ZW251 provides a new therapeutic modality option targeting GPC3 for hepatocellular carcinoma and represents an emerging opportunity in oncology that has yet to be fully realized. With a potential best-in-class design and differentiated mechanism, we believe our pipeline presents meaningful opportunities for both </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">strategic partnerships and value creation, and we look forward to initiating a Phase 1 trial for ZW251 this year.&#8221;</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:105%">Zanidatamab Continues to Progress with Initial FDA Approval</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In November 2024, the FDA granted U.S. Approval of Ziihera&#174; (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2+ (IHC 3+) BTC. Under the terms of the Jazz license and collaboration agreement, we have earned a milestone payment of $25M based on the FDA approval in BTC. We are also eligible to receive up to a further $500M in regulatory milestone payments and up to $862.5M in commercial milestone payments, as well as tiered royalties between 10% to 20% of net sales by Jazz.</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Ziihera</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> net product sales by Jazz were $1.1 million in 2024 and</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> 4Q-2024 after the initial product launch and availability in December 2024 following FDA approval in November 2024. Our royalties from net sales by Jazz have been reflected in our income statement in 4Q-2024.</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2+ BTC. Zanidatamab is also being investigated in a number of additional tumor types, including Phase 3 trials in gastroesophageal adenocarcinomas (GEA) and metastatic breast cancer (mBC). The HERIZON-GEA-01 trial is evaluating the potential of zanidatamab plus chemotherapy with or without tislelizumab as first-line treatment for patients with advanced&#47;metastatic HER2+ GEA and top-line progression-free survival data from this study is expected to be available i</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">n 2H-2025. The</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> EmpowHER-303 trial is evaluating the potential of zanidatamab in combination with physician&#8217;s choice chemotherapy for the treatment of HER2+ mBC for patients who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment. </font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:105%">Legacy Collaboration Agreements</font></div><div style="margin-top:11pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">In January 2025, we achieved a $14.0 million cash research milestone associated with a clinical milestone under our 2016 platform technology transfer and license agreement with GSK.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%"> Under the terms of this agreement, we previously received an upfront technology access fee payment and we remain eligible to receive research, development, and commercial milestone payments of up to $1.1 billion. In addition, we are eligible to receive tiered royalties on worldwide sales.</font></div><div id="ia74eca56e7e24e589e0da48e640cde01_4"></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Financial Results for the Year Ended December&#160;31, 2024</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Revenue was $76.3 million in 2024 compared to $76.0</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">million in 2023. Revenue for 2024 included $25.0</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">million of milestone revenue from Jazz in relation to the FDA approval of Ziihera&#174; (zanidatamab-hrii) for the treatment of HER2+ BTC, $37.5 million for development support and drug supply revenue from Jazz, $8.0 million of milestone revenue from BeiGene in relation to the acceptance by the CDE of the NMPA in China of the BLA for zanidatamab for 2L treatment of HER2+ BTC, $2.5 million of milestone revenue from GSK in relation to the sequence pair nomination under the 2016 licensing agreement, $3.0 million from BeiGene for drug supply and other research support payments, and $0.2 million from other partners for research support and other payments. Revenue for 2023 included $71.5</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">million for development support and drug supply </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">revenue from Jazz, $1.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">million from BeiGene for drug and other research support payments, and $2.9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">million from our other partners for research support and other payments.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Research and development expense was $134.6 million in 2024 compared to $143.6 million in 2023. The decrease in research and development expense was primarily due to a decrease in expenses for zanidatamab as a result of transfer of responsibility for this program to Jazz, and a decrease in expenses for ZW171 and ZW191 as the majority of manufacturing and IND enabling studies were completed in 2023 prior to filing of IND applications in 2024. This decrease was partially offset by an increase in manufacturing and IND enabling supporting activities for ZW220 and ZW251 and other preclinical and research activities. Stock-based compensation expense increased primarily due to new grants during 2024 and a lower expense in 2023 as a result of the cancellation and modification of awards in respect of employees transferred to Jazz.  </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">General and administrative expense was $61.5 million in 2024 compared to $70.4 million in 2023. The decrease in general and administrative expense was primarily due to a decrease in external consulting expenses for information technology, legal fees, and other expenses for advisory services, insurance and depreciation and amortization expenses compared to 2023. This was partially offset by costs incurred due to the termination of our long-term facility lease in Seattle in 2024 and an increase in stock-based compensation expense over 2023, primarily due to new grants during 2024 and reversal of compensation expense for options cancellations and modifications in 2023. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In 2024, we recorded a non-cash impairment charge of $17.3 million as a result of our decision to discontinue the zanidatamab zovodotin clinical development program which utilized the technology represented by acquired in-process research and development assets.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income, net was $20.5 million in 2024 compared to $18.8 million in 2023. Other income, net for 2024 included $19.9 million of interest income and $0.8 million of foreign exchange gains, partially offset by other miscellaneous charges. Other income, net for 2023 included $19.7 million of interest income and $0.3 million of miscellaneous income, partially offset by $1.2 million of foreign exchange losses.   </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Income tax expense increased by $6.7 million in 2024 compared to 2023, primarily due to an increase in U.S. taxes under the Subpart F income rules and due to an increase in deferred income tax expense due to changes in net deferred tax assets and liabilities and the valuation allowance in respect of these.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Net loss was $122.7 million in 2024 compared to $118.7 million loss in 2023. The increase in net loss was primarily due to an impairment charge recognized in 2024 related to zanidatamab zovodotin and an increase in income tax expense, which was partially offset by lower research and development and general and administrative expenses. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had $324.2 million of cash resources consisting of cash, cash equivalents and marketable securities, comprised of $66.1 million in cash and cash equivalents and $258.1 million in marketable securities. Based on current operating plans, we expect our existing cash resources as of December&#160;31, 2024, when combined with the assumed receipt of certain anticipated regulatory milestones, will enable us to fund planned operations into the second half of 2027.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Zymeworks Inc. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks&#8217; mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company&#8217;s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company&#8217;s proprietary Azymetric&#8482; technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera&#174; (zanidatamab-hrii) 50mg&#47;mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned by mid-2025. In addition to Zymeworks&#8217; pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow &#64;ZymeworksInc on X.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cautionary Note Regarding Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release includes &#8220;forward-looking statements&#8221; or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks&#8217; expectations regarding implementation of its strategic priorities&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> the anticipated benefits of its collaboration agreements, including Zymeworks&#8217; ability to receive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> any future milestone payments and royalties thereunder&#59; the potential addressable market of zanidatamab&#59; the timing of and results of interactions with regulators&#59; Zymeworks&#8217; clinical development of its product candidates and enrollment in its clinical trials&#59; the timing and status of ongoing and future studies and the related data&#59; anticipated preclinical and clinical data presentations&#59; expectations regarding future regulatory filings and approvals and the timing thereof&#59; potential safety profile and therapeutic effects of zanidatamab and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Zymeworks&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> other product candidates&#59; expected financial performance and future financial position&#59; the commercial potential of technology platforms and product candidates&#59; Zymeworks&#8217; ability to satisfy potential regulatory and commercial milestones with existing and future partners&#59; the timing and status of ongoing and future studies and the release of data&#59; anticipated continued receipt of revenue from existing and future partners&#59; Zymeworks&#8217; early-stage pipeline&#59; anticipated sufficiency of existing cash reso</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">urces, when combined with the assumed receipt of certain anticipated regulatory milestones, to fund Zymeworks&#8217; planned operations into the second half of 2027&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Zymeworks&#8217; ability to execute new collaborations and partnerships and other information that is not historical information. When used herein, words such as &#8220;plan&#8221;, &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;may&#8221;, &#8220;continue&#8221;, &#8220;anticipate&#8221;, &#8220;potential&#8221;, &#8220;will&#8221;, &#8220;on track&#8221;, &#8220;progress&#8221;, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks&#8217; current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation&#58; any of Zymeworks&#8217; or its partners&#8217; product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable&#59; Zymeworks may not achieve milestones or receive additional payments under its collaborations&#59; regulatory agencies may impose additional requirements or delay the initiation of clinical trials&#59; the impact of new or changing laws and regulations&#59; market conditions&#59; the impact of pandemics and other health crises on Zymeworks&#8217; business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks&#8217; behalf&#59; zanidatamab may not be successfully commercialized&#59; clinical trials may not demonstrate safety and efficacy of any of Zymeworks&#8217; or its collaborators&#8217; product candidates&#59; Zymeworks&#8217; assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect&#59; inability to maintain or enter into new partnerships or strategic collaborations&#59; and the factors described under &#8220;Risk Factors&#8221; in Zymeworks&#8217; quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ZYMEWORKS INC. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Loss and Comprehensive Loss </font></div><div style="margin-bottom:15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Expressed in thousands of U.S. dollars except share and per share data)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.787%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(unaudited)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(unaudited)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development collaborations</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,031&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,926&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,304&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,012&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,063&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,524&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,621&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,619&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,185&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,823&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,506&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,446&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment on acquired in-process research and development assets</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,287&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,248&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,347&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,414&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,065&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,217)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,421)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,110)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,053)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,217&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,499&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,811&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,791)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,204)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,611)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,242)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) recovery</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,715)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,722&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,084)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,506)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,482)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,695)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,674)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized (loss) income on available for sale securities, net of tax of nil</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive (loss) income</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,459)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,787)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,044)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,618)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.62)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.72)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.62)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.72)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common stock outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,660,703&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,829,828&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,846,681&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,863,010&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,715,961&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,829,828&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,878,738&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,863,010&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZYMEWORKS INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selected Consolidated Balance Sheet Data</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Expressed in thousands of U.S. dollars)</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.333%"><tr><td style="width:1.0%"></td><td style="width:68.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.499%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br>2023</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and short-term marketable securities </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,776&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,327&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,815&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,477&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,122&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,428&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,930&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,212&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,024&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,091&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,880&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,838&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,992&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,456&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,771&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,029&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,311&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,323&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,074&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,768&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,806&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,091&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,880&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Investor Inquiries&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Shrinal Inamdar</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Senior Director, Investor Relations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(604) 678-1388&#8239;</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ir&#64;zymeworks.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Media Inquiries&#58;&#8239;&#8239; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Diana Papove</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Senior Director, Corporate Communications</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(604) 678-1388&#8239;&#8239; </font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">media&#64;zymeworks.com</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>zyme-20250305.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9d5d0ff3-fe4a-435e-bf15-0ec2343d4c51,g:1e625152-6b29-46f4-847a-3baffa6d17a3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zyme="http://www.zymeworks.com/20250305" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.zymeworks.com/20250305">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20250305_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20250305_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.zymeworks.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>zyme-20250305_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9d5d0ff3-fe4a-435e-bf15-0ec2343d4c51,g:1e625152-6b29-46f4-847a-3baffa6d17a3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8e40470d-dc4d-440f-b5ed-f094ad8008b9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_33da4a63-ba4c-458e-8602-ce2981fa6ab5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_477ed1c9-3252-41d6-9cc1-b593ce236149_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7ec3d9f7-4498-4d9c-9e0c-78fe2d50c925_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_92c1a3fd-e477-4d29-b449-77bbaa41ce5c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_94a40107-5844-4c9f-9625-7364f5caa34e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1730e18c-42df-41d2-a9e8-aea413e11ac5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_05630b43-d1f7-4365-a515-13070d3cb1c0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d2eecc7c-a055-48e9-8f92-584f83e5154d_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6739ee29-01e8-438a-b763-d27731a58283_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_724503c3-186c-4a86-8009-6487b14b3210_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_28743bf8-828e-4aa2-8d7f-1578b167624b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_97020152-104f-48cb-ae1c-028086925db3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_13325923-61ea-461a-a292-fbec123cabc6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ac25f9e1-74e4-4c56-ac15-17fcb63965f7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_dfc003d1-df30-4796-a352-1db332700e72_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_28d707f5-f7e1-427d-ae13-ee7e49e160cd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_29688695-929f-4d0d-8b29-6b2d05d4652d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3373c0ff-de09-4d09-af7c-b63bf05e8e28_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ef4e2401-e899-4f0f-969d-7f68ca8ab5a6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cb28d70c-cc62-42b8-922a-de145a2ab9e8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_830293b4-f925-49c7-80a6-71607f030e20_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>zyme-20250305_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9d5d0ff3-fe4a-435e-bf15-0ec2343d4c51,g:1e625152-6b29-46f4-847a-3baffa6d17a3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zymeworks.com/role/Cover" xlink:type="simple" xlink:href="zyme-20250305.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.zymeworks.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f66ae841-e8ac-4672-a8bd-e603292297fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_DocumentType_f66ae841-e8ac-4672-a8bd-e603292297fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_64e5c56b-a7c5-4cea-8afd-94f5f005ab38" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_DocumentPeriodEndDate_64e5c56b-a7c5-4cea-8afd-94f5f005ab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3f0aef37-0bc7-4212-9341-433dd766d9fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityRegistrantName_3f0aef37-0bc7-4212-9341-433dd766d9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3245d04b-1075-401e-80d4-d2f3c7b22a28" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3245d04b-1075-401e-80d4-d2f3c7b22a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c4aca1d8-7464-41df-9a3f-0090aca54a2e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityFileNumber_c4aca1d8-7464-41df-9a3f-0090aca54a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c56db34d-da92-4f72-bed5-28ac30768fc0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityTaxIdentificationNumber_c56db34d-da92-4f72-bed5-28ac30768fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_40e6e65a-075b-4fad-aebb-ccc915c99bb1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityAddressAddressLine1_40e6e65a-075b-4fad-aebb-ccc915c99bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b843cd1c-0f14-4af0-a10c-abba6aa944c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityAddressCityOrTown_b843cd1c-0f14-4af0-a10c-abba6aa944c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cdaa7432-d451-49c3-a378-2b42052ab413" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityAddressStateOrProvince_cdaa7432-d451-49c3-a378-2b42052ab413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d9c4906c-6579-473c-bc65-15721394d786" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityAddressPostalZipCode_d9c4906c-6579-473c-bc65-15721394d786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1005d857-bdb0-46d3-83b3-0860fab6184a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_CityAreaCode_1005d857-bdb0-46d3-83b3-0860fab6184a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_78456d05-b1a9-4750-b656-76b70b258c41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_LocalPhoneNumber_78456d05-b1a9-4750-b656-76b70b258c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_6fa6fd84-b69c-4f43-8ee1-d9cf83b83728" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_WrittenCommunications_6fa6fd84-b69c-4f43-8ee1-d9cf83b83728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_78a0c88b-5f65-4ea1-8eca-c2661982d08e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_SolicitingMaterial_78a0c88b-5f65-4ea1-8eca-c2661982d08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_6ad45583-4014-4590-a4eb-b095cbb0af6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_PreCommencementTenderOffer_6ad45583-4014-4590-a4eb-b095cbb0af6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_4dbccdf8-4ae7-410c-a33a-9e4f3490b624" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_4dbccdf8-4ae7-410c-a33a-9e4f3490b624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_94e08b09-feb4-4c52-a8a8-04b028157b41" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_Security12bTitle_94e08b09-feb4-4c52-a8a8-04b028157b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d8cfefee-20f9-4d5e-a935-3c18499be9fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_TradingSymbol_d8cfefee-20f9-4d5e-a935-3c18499be9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ebaa56c6-8222-48b4-bb24-e8b9495594c2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_SecurityExchangeName_ebaa56c6-8222-48b4-bb24-e8b9495594c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_133d4bb3-113a-4ae4-bde5-c291d5bd5e5a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityEmergingGrowthCompany_133d4bb3-113a-4ae4-bde5-c291d5bd5e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2e2472af-4db8-4932-9aee-6406897e68ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_AmendmentFlag_2e2472af-4db8-4932-9aee-6406897e68ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7cab7b1a-0a92-48c4-a5cd-3e162d9fe71a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_05e79d97-2b47-4c29-921b-2e3c200072fc" xlink:to="loc_dei_EntityCentralIndexKey_7cab7b1a-0a92-48c4-a5cd-3e162d9fe71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>zw_logo.jpg
<TEXT>
begin 644 zw_logo.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0!,17AI9@  34T *@    @  8=I  0
M   !    &@       Z !  ,    !__\  * "  0    !   !<J #  0    !
M    G     #_[0 X4&AO=&]S:&]P(#,N,  X0DE-! 0        X0DE-!"4
M     !#4'8S9CP"R!.F "9CL^$)^_^(-7$E#0U]04D]&24Q%  $!   -3&%P
M<&P"$   ;6YT<E)'0B!865H@!^8 "  #  < ,P 286-S<$%04$P     05!0
M3                        /;6  $     TRUA<'!L
M                                               29&5S8P   5P
M  !B9'-C;0   <    'N8W!R=    [     C=W1P=    ]0    4<EA96@
M ^@    49UA96@   _P    48EA96@  !!     4<E120P  !"0   @,86%R
M9P  ##     @=F-G=   #%     P;F1I;@  #(     ^8VAA9   #,     L
M;6UO9   #.P    H=F-G<   #10    X8E120P  !"0   @,9U120P  !"0
M  @,86%B9P  ##     @86%G9P  ##     @9&5S8P         (1&ES<&QA
M>0
M                                                 &UL=6,
M    )@    QH<DA2    %@   =AK;TM2    %@   =AN8DY/    %@   =AI
M9       %@   =AH=4A5    %@   =AC<T-:    %@   =AD841+    %@
M =AN;$Y,    %@   =AF:49)    %@   =AI=$E4    %@   =AE<T53
M%@   =AR;U)/    %@   =AF<D-!    %@   =AA<@      %@   =AU:U5!
M    %@   =AH94E,    %@   =AZ:%17    %@   =AV:59.    %@   =AS
M:U-+    %@   =AZ:$-.    %@   =AR=5)5    %@   =AE;D="    %@
M =AF<D92    %@   =AM<P      %@   =AH:4E.    %@   =AT:%1(
M%@   =AC8453    %@   =AE;D%5    %@   =AE<UA,    %@   =AD941%
M    %@   =AE;E53    %@   =AP=$)2    %@   =AP;%!,    %@   =AE
M;$=2    %@   =AS=E-%    %@   =AT<E12    %@   =AP=%!4    %@
M =AJ84I0    %@   =@ 1 !% $P 3  @ %  ,@ T #$ . !$  !T97AT
M $-O<'ER:6=H="!!<'!L92!);F,N+" R,#(R  !865H@        \]@  0
M  $6"%A96B        !O#   -N8   #"6%E:(        &'D  "X?@  %')8
M65H@        )>8  !"<  "]^6-U<G8        $      4 "@ / !0 &0 >
M ", *  M #( -@ [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L
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MU___^[?___VF   #V@  P/9M;6]D        $*P  -#!,$%65-C_M8
M                =F-G<        P    )F9@ #     F9F  ,    "9F8
M   ",S,T      (S,S0      C,S- #_P  1" "< 7(# 2(  A$! Q$!_\0
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M# P,# P,# P,# P,# P,# P,# P,# P,# P,_]T !  8_]H # ,!  (1 Q$
M/P#^_BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /_0_OXHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHK)UC5]-\/Z7/K6L3+;VMLA>65S@*!W-*4E!-MZ :U%?E?\ $/\
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MDDGMG&*_?CQA^P7^SMXOUI]<ET@6DDK;G$)(!/Y_RKWOX8?!7X:_![3/[.\
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M%?#B3"QE,6\L<G'XUQ'_  ]DO_\ H68_^^F_^*K\]K>*7#M*HZ<J[NM/A?\
MD<$LSH)V<S]JJ*_%/_A[-J'_ $*\7_?;?XU]-:_^VOK^F_L]:/\ 'O3- %S#
M?SO%<09/[K:7&>O3Y:Z,)XD9'B5-T:S?(N9^Z]KI7V\RH9A0G>SV/T2HK\LO
M@3_P4=LOBM\2K'P)KVCIIT=^2JW ;@$ D9R>_2OU-KW\AXBP&;T77P-3F2=G
MTU^9O0Q%.JN>FPHK\H?C'_P4NLOAU\0]0\&>']'34H+%_+\_)Y..>Z]&XKVK
MPM^UUXGUC]G35?CUJ_AX6R6<H6WM]W^M4E1OZ].:\BAQ]DU6M5H4JMW!2;T=
MDH[N]O\ AS*..HMN*>Q]Z45^1'P]_P""H5EXH\3P:1XAT:+3K-\M+/D_*!^-
M<GXN_P""K=S::Q-:^#_#L4]K&Y57N&(+ =_E/>N"7BAP\J7MO;Z7ML[_ '6(
M>94+7YS]HZ*_';X=_P#!5.TU;Q!!IOQ T%+.VG<)Y]J2=N>YWMTKWK]HS]O[
MP/\ !N:TTGPE$FNWUU MP,']VJ.,H2=P/-=5#Q%R&KA:F+AB/=C:]T[Z[:;O
MY%1S"@XNIS:(_0^BOP[B_P""LOC#?F;PQ9;/9I,_SK[G_9G_ &V/ W[0MRWA
M^2%M+UA%R+>3I)_N<G]:64>(N1YC76%P];WWLFFK_>%',*%1\D'J?;M%>-?&
M[XV^#_@1X+E\9^+I/D7Y8HE^\['H!7Y8:M_P5CUMKQE\/^&(&A_A\\ON_P#'
M&KKSWC?*,HJJCC:UI]DFW^!=?&4:3M4>I^VE%?A[_P /7?'"_-<>%;0+]9/\
M:^@_@C_P4I\$?$;Q+;>$_&6GMH]Q>.(XI\YBW'@ \L>:\W!>)W#^)JJC&O9O
MNFE]]C*&98>;M&9^G]%?%7QZ_;K^"_[.7Q1\.?##XF-/:2>)TWVMWC]SC..3
M7V9!/'=0+<0G<CJ"K>H-?I%7"U:<8SJ1LI;/N=%'$TJDY4Z<KN._D6:*^:OV
MH?VIOA;^R7\.S\2/BG<-%9M,D"(GWF9CCBN;_9,_;,^#O[97AG4/$WPEG=TT
MJ<6]S%+PRLPR/TJUE^)=#ZRH/V>U^AD\=05;ZOS+VF]NI]<T4UF55RW %?%G
MPS_;I^#'Q;_:%U?]G/P*T][J^B>:+J=!^Y5HN&0GUXJ*.%JU5*5.-U%7?DC6
MKB:5)PC4E9O1>9]JT5\??M'?MQ_LZ?LN%-/^)VOQ0ZI,NZ*PCRTS#V50?UKX
M'NO^"YO[/4$S)%X3\1S(/NND(P?UKNPN18_$P]I1HMKN<.*SO X>7)5JI,_;
MFBOQ=\/?\%O_ -F35+Y8=>T;6]%MC]ZZO(<1K]=N37ZE_"7XT_"_X[>%(_&?
MPJUFWUG3I,?O8">#Z$'!!K/&Y/C,*N>O2:1I@\UPF*=J%5-GJ]%?'/QK_;<^
M"GP"^+6B_"#XB736E_K<)GBE/^K6,;N6/_ #7Q[\1/\ @M+^S+X)\2W/A_1-
M-U?Q'':N4:ZTZ+,1(.#@MMJ\-D>.Q"3I4FTU?Y$XC.L'0;56JE;0_8BOE/\
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MK\2[_P#X+D?LYVLYAM/"_B*[0=)(H5P?<9--L_\ @N5^SG<3".^\+^(K./\
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M;_P3T^&?A;]KS]O/XF_%_P".=NNOW&@WLMO:Q70W*IC<(CX/H@VU_2U#\-O
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<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46610674890368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  05,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zymeworks Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-3099146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Patriot Drive, Suite A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Middletown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-8744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZYME<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001937653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,NP#<'\II3DT[+ZU_-MA_#]02P,$%     @ "8%E6I^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  F!95I]QI@?2 0  ((0   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  )@65:GZ ;\+$"  #B#   #0              @ &,#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    (  F!95J7BKL<P    !,"   +
M  "  6@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  F!95JJQ"(6,P$  "("
M   /              "  5$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  )@65:)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  )@65:99!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="zyme-20250305.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zymeworks.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="zyme-20250305.htm">zyme-20250305.htm</File>
    <File>zyme-20250305.xsd</File>
    <File>zyme-20250305_lab.xml</File>
    <File>zyme-20250305_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zyme-20250305.htm": {
   "nsprefix": "zyme",
   "nsuri": "http://www.zymeworks.com/20250305",
   "dts": {
    "inline": {
     "local": [
      "zyme-20250305.htm"
     ]
    },
    "schema": {
     "local": [
      "zyme-20250305.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "zyme-20250305_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zyme-20250305_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.zymeworks.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zyme-20250305.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zyme-20250305.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001937653-25-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001937653-25-000012-xbrl.zip
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M$L"1<STW6%V XP\O![;=.]9GJ<*FCA?@9W6:5A<!]E9$,0*Q,4WAD<;$"T:
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M*3B/Z;_C74']Q<_VKRA]^WM&UOLN0[\ &1O3($[0CAJ#A@,! R0$'Q)1PC;
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MIQ/31' Z3\M.RJ_RB=R/RV%AS+I2.%E6=)S[C5])@!/SJN#6:F'%/]:45<R
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MT]I$52%TO"K%'5#$4J0=[$<?Q)XNB1I3-$]&S)M@@U&X'$^7[R9D:4SA53B
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MA%K<%O9\T6P1LDX &K%L BT4,ZGRS&RVUKO$;1H'ZD]9=UHZD.L<!2]<?">
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M_H M6I>F<2F KXRKJZOF]ZSS&NZ7-@3U[1@_O.QUCK-;P!Y%E^I_JC4?I+S
M\Q2L*L0Q,/\'8$?C$Y^PB%I'WLH6VL:[  ?23(P+W3*T6O)=J;D<)%L_RPRO
MC%OK7 F%.&/=-*]:A!N>.E_6$A7K]OPEPE"3GRGI*VU@G5U47+'H7&/R2:BA
M1\66G NEWNW^B;[_(K_I1$;'K&&[38V2;$9SW:4%G-UJO2FY]8V.H>9K=(IK
M-#.4KAY9BOQU,#.-$;"$%!P)V/C2 L/&A\(*U/0O0U&E_"ZC",HECS(R$YFQ
MKMT5% <%IE;S3#@LU!V6*NS==P+*65MYR&($MNQ8R*IS_+&FQ7>A56L%8"QW
M*E05^DZM%?1%U1"3-7W >7$\BFI.U@4A;:FA1\TG)WZ1<:FE'I_\)AS'(?E,
M%1>0I:O3$GH$,\GZS(R1A+(*S]+TF$+0JLZ7TXMH7J'NDR1,+AHR*SN5\V-8
MDM(N=0.B=#<)=EHUZTBY#M[BT>5J14):+J]8'%93',>FMK*&R]3#"Z:>+#*1
M^] .2[XK=1K"8S"62^<(5.,0X298A>N;,OW-P6UR))H6:G3@:Y5DWV5*V2F;
MZ;*:97HLHG?AI25@B9*.TO4*"M6%+R@'*:?50J?,0IM=(?JT&"I9MYWK9!;6
M L3C>>$)Q>'I:_IU%"]G8>;"@;1U=R\L1]H-OEW.=?GPLT)H>J&R].8-KNH_
M%H&+(2-]VO9=?72<8I ,'!Z'*LI6X^V5Y"!* CQ0G%\']E<=B.TB_6O-AT=C
M[>NXA=-K4CAY6@O6@F+ Y>$W@<KE%^J>T/ZB<6V) 98<1JL<&B&0?:5I?$$$
MT7@V%.P"6]X"+'O3P5=E&B-DE1&<O55#35I:_E@*I.5/9VR^_)'FJ>7/<PI8
MOI()CN4+F/E9_@P! /; UY5%5/MN]CE)"Q <..1*AP\(RK*KERQE&AODTNBM
MN;'>3UCJ'D0#J6 /+Y>E2?,8BU(++]6K<TX[=1.+UI(IAXF-L;)&IC[52Q'E
MQ6RX,EXHJ-Q EXAC?AYS'9'*O) V4JH!58<D"4=$3CJ+J1UJP?Q'ZI$SCN?T
M)\K,4#U;O0VM2(9-X\3SKJ%-ND=F$](0R&_5&E8)WP6#48[5BJB5O;"#8E!-
MR0%EX\MT%H:G IF)A4<*59.9Q*N+9R!&AQ)6F"N^F_(L)*E40_&9($Y(K*GQ
M<2M+2Z[&3]7ZV1WR14=. &=UDB9ZQFEA(*<3I)X>, >W(.ZHZ$%->PCH74ZQ
M$XD1JIF(?%4AXUPD,:\#_V)!GP8J5E_C6[1RQ)O9H ORJYFRU ;'1!'%=V5I
MS"G8YN:&4H>K+@Q"8<R$9^0OE9*IPAR@NJM:U?L5333M%-#0 [QCA.#PV%R]
M3<R@^>2H].44E'D6(<@M.P#FI4#"6#**LAVHEONB!4@=%G)?A0$GF:<I@]8K
M7K4RNXH'F( 5)108 '6(SL*"ZLR9L*:CE;QR;:W')W.;<CS5%?$VAE^0#CQV
MI3QBN9M\>\K=S?.>9<N%<"N?Z?GN4KI,@?3Q;5=8$4+-YRMDH=^B9R[6Z)07
MA:* D_8PB%.4BWJ_F8.=6U5%*:4W6>8,R]']9@$M1.EJ1CVECW 2-4[6P#6H
M.#@J/PI'PTV"INA!:J(9X7@6FAX@<[@+63Q7WK><<=#W%B9Z%\?Z<S2[F32Z
M;V"\A?.MY[YU'E(N5N6#P;Z?$;<68F+89Y_Y;QFQF"6^W9+SIU=;?(^O8EZL
M^2)!*+<&B^3V)PY<((L\B&0&5]K22-D+MB=F@;+87!D#:B=+2;J" )6,J^RR
M3R+^:KR5W]'Q5E%""NHUEZIY5LVSEZ_J0AAY13^C$ O%+V?QT%.LH)"5# =.
M$*I!P[+:38$F&.'A,7<K(_W@/S0GP:4<2$%_NRS"645-AU5^,K4LDO%0JTRF
MY:J;)3=K,(H7:<5N*GV/TVQ&*.6)D&67!,E^*L=2;W.E@4B9TCVG9!+20CPE
MA4N*V6,.C49)R1\7TI;RK[6V,?$.Y';)%ZTC$(E?U2!";3Q(&E#:B'^;LC1&
MT^W:"#A^?<9<KFK9J-(&A80,@>'Z)I83\! KWC7=9(H3"R39E5F -I$[OH\.
M73(@,$^ETQ \<@HT2NHPA0M8&DA:[U+03,CKG X9#J:I;L2=!1_#O-'<E/UE
M^G8\8N!(0]"13)'Z18]<KK.^2/>Y.BME,UH>HARNM5$Y'+Z]^<OOGWZ[,,X_
MG*Z538^X*RJB/07>Q!<$$"%=%-SBL?$.*YZIL@!+7/D41RH 4]/'FU8'=W<!
M;CK8P1L9-9"%#BAD8367#D;5%BXJQ2C6LH)>H2)C.*#]Y%]HSZR^Z+S\I$,Z
MJ*K<U0P4@6AID/8-8WZD?SEV10QR=7XD?-HVW72\N%Q)30R]:4=>SGFAV9+\
MD  3)*Y^LKK<I$L_)N[JM4Z["5RU]G*K::V]=MVR5KO9[W1OM>SUUX:=V]UY
M[6:MYK"[_G+E-ML?].]]LU933@V[Y\VVFFV[O=&R/Q+E2NH%!HG!J?KGB_:+
M&T/F(;J(_N2H9<BA=?I!V1K#S=>PPV^XBGR7E60VCX]7B]*(]Q:U5.$6^;:V
M^Y9V@YN$74O.7,59F._A>]-X:=J7T;;,)?VX#*H:W%N"NV2HVAHP/QAY;["&
MTC]D]J"&H_< :=A<@PP)V;7HV &\%^;4/10D:E K4+?O NH:FC7A5H-P*REZ
M]T()KGA8JY-FR<-*?9:Z6&-X^ @&QD-!_3$I^0Z K2Q([[+Z#G:XM51P',ZW
M-UYA.SLB'C5)\E:$LW366Z&E7N-QU[BKFE,$;=#/8;/?K2AQVZWKAN$MIKB6
MB7\;6+2,;57S+KC\U9V.6#P:-5Q6ZFS@2;?:EAQ.<)=C:JK>XKCWJ<1JHMLG
MHK-ZYM#NU417$]TCGJW?,]NM3DUT-=$]+M&U+'MW1/?D/;#?L]E,>IH6%8K6
M'MDS6>.Y>&2MZSRRM=1N;P>(4GU1/:':[INM7GOO-?D3QY+=-;OV_MM;3QQ+
M5KMC]NS]#P \=31UVF;/&NZ](;D?>G;]&P%NI6E+0+$O9-<SK4%W2ZJ[!O,/
M)1PVM3*?*)8ZYL#>UAZJL?3(6.I99K>U;="SQM)C!VQ:9J>S0RS=DS^[F6XM
MU+FH^QOXY2.<UOX8S03E*#C/Y[OC8*CM7[MQ0X',T[00J3G0/JX-^1I--9KN
M;E+U37O0K[%4;2SMG)F>?'KE<Y#@&+25),M=_.#-*D?WA 2[;=/N#&YG+VY<
M0KLO]OZ3PFRG9;8[VZJ &K-[@%G;:IL=:]O41(W:O4!MQVSU;AFQ?%C4/JIG
MOPO8TZP"^8[P;$[273+33XHP#VS;M*W^2H_)O;79[(N;\<2P"IK$MFJL/BVL
M6NV^:5FM&JU/#:T#L]5M5PRM]YM9K[*!L/*NY6>63>^ KJ@3@)5'$IAI-9*J
MC22[97:&VU9#U5AZ["3*P!Q8VY86[FLN?6<>]XB/@X@77EY^R^C\TS3Y^F9_
M6/MG3PVK0]-N=6JL/C&L6CVS9]7,^N30"MS:L2N&UD?-W#_"P.'R$1[GF5%@
M'*C4_2&^2"* ;<[O4":WOS;I0=?L6]W-B;%V&A[=_^[;VS9,UTAZ;"[JF:W!
M%@98C:#'+DOJW;(FJ?:[-X#N!YX8'OC>#V/2/-&I'1L>OMI\A0G?;JM7,6/V
MD4;+U.2[]^1K=<S.H&J^6$V^-?EN2+ZV;?:&6[AO-?W6]%N=4Q]8UL#L]:L6
MN7X>L3!9?>(LO%[K *WX0Y4[6QP<MOUP]7T8EU6O\2#CP^[:;KV+7FMBBC]\
M]?YH=Y$7J//ZD@F/WK&&KZ6-&;YL+7N;*-5OT3LAV3=ZW:_PGF7;]<'P%@6%
M%3(ZGCAZ+#07ZS;>:B/IH-T9UCQ46?1T=SBI^WF8IJK+^B8#]>X)VZ=56;"5
MZJW;-_< I;=1US5B]P"QVZGX&J5[@-*MS8*ZR_H^P+[X?O@Z"_TLX\AVQ^QT
MM_>9JB%0ZS3(<R=?RS;[@R<Z"Z$FWV= OFVSU:E:%J^FWYI^M\A"6X.*T:^R
MW/4N]);E'.(=Y L+IVW#D=P@Q538PG%WG=*LM[B++3YE%],NEC<;H8Q'SP+?
MB*<LXK=_M=JF&91ZC>JL\:Q>^?*:Q<*Y2[/$4[-XRHY8<;NFU6QOT3U<O9ZD
MFMSVC-SL+4;$U>16D]O=O+9F;XO&C9K<:G*[([GU=T-NS^J-OF?"2Q/NWND-
MZ$^,5\J.6'%>V<[PK%X!8TUN>T9NVQB>-;G5Y/:(AF=-;C6Y/:+A>8_D]I1?
MYD5Q_2_T!W<;#+;$)CR+[2>!\]4(TB1.F(]'N7V<?Q]Z_NHU'B2?M1\.5VF<
M/SOUTVS@Z7?,7J]E]EO;OB.\>KK\J6.J90[L(?Q_V^E=-:8>&U-=<]#IF;W!
MMO/-:TP],J9Z W/0:YLMJ[7W;8S[H6+7Q#0W(K/]G;@(2K9O=<UA;X<O/-A!
M2],^8NJV2K;&U Z4;']@]MLUIBJ.J5LKV?M.'/Z8X,0:W2-?F+BCMMNWX3QA
M$ M\/>E1Q#V6B$M^?"7<9*K.4KQ+/N&HE=_"1G& ^FWE%@GXGW\:X2[4Z66C
M?N'?:5;?'+();XPBSKXVV#CAT1'SKM@\7GS\3/@YG >P\RT?6ER*11-8C8JW
M[4>8-]0O#4']^>_W;[[\_NFW"^/\PVES<<N/,'ZA?%,7W.,.6"S&:>!343O#
M/UXSC_D.-RZFG"?&&4O8RG:78*N(9;@SZ!Z\^19&/(YA]\(WDFF0PFINC/.9
M_FA>- TW\#P6Q8=;'Z2$P![U^/9&\<U%T4."(.=CJO%V$ !AS(_T+\>NB$./
MS8^$3^O13<>+!T)C>]FX1L$D+RN6' Z;[78;N5*9^>K!BF&;Q+!+TE!>ZPV:
MW?;ZRZVFM?;:=<M:[69GV+_5LM=?&_8[#[/9X:;+ENACC48_\/D=&DJVB+'N
M_*O7'/D>-U)B?3C<!WWU..;'\":Y)SU.[O#9B$=&VS)14MDMN[-!^N(9@:.]
M 3@>GX?6-I2UMFL/VL$C;\%]^Y1 +">L$S MDO5O%]SW1-@#8KH\EE@%3*^9
M,I)&$<@U@Q'&GV/?U\X9?.VTV,?PWM90!8NGIN' OP;_.Q67S ,:B0WP,8QX
M&D1) Q3AS #K^2M7UG<V+]8H'UYWYU#('M?F[%]1N&UWS7Y__U]A7E/=/E%=
MN]\QVW;EWLG^@':!)+EVE0V$$\>!<X#PC\#9 $T TOZ95=5TN^; JF=+5QQ+
MUM#L]+>5'0^.I0<T+O= =J@W<2RX&,^L6L#"?-D.<V5U5G-#X6%5[V6T.P](
M[&)..N'C70!.\-8^YA/7<,.!V:GK1:N.I8%E#ML[K$"L:)!K=^:'E\F29VF
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MD=9%GZ<G]9*R5SJPG>^%W@3^&\BAW_A_4$L#!!0    (  F!95K%^BH=8 (
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M&X[?/.SH/KH7XH_?_!=02P$"% ,4    "  )@65:\N4WSJ4K  !0FP$ '@
M            @ $     97@Y.3%Q-#(P,C1?96%R;FEN9W-X<F5L96$N:'1M
M4$L! A0#%     @ "8%E6FI&)];H$0  L9D  !$              ( !X2L
M 'IY;64M,C R-3 S,#4N:'1M4$L! A0#%     @ "8%E6L7Z*AU@ @  _ 8
M !$              ( !^#T  'IY;64M,C R-3 S,#4N>'-D4$L! A0#%
M  @ "8%E6FYPD%H("@  ?50  !4              ( !AT   'IY;64M,C R
M-3 S,#5?;&%B+GAM;%!+ 0(4 Q0    (  F!95HI*>NVJ08  . P   5
M          "  <)*  !Z>6UE+3(P,C4P,S U7W!R92YX;6Q02P4&      4
,!0!0 0  GE$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>zyme-20250305_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zyme-20250305.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
        </entity>
        <period>
            <startDate>2025-03-05</startDate>
            <endDate>2025-03-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001937653</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-03-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Zymeworks Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-41535</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">88-3099146</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">108 Patriot Drive, Suite A</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Middletown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">19709</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">274-8744</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.00001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ZYME</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-21">2025-03-05</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
